Axsome Q2 FY26 net loss widens to $51.3 million; net product revenue climbs 46% to $218.4 million year over year
AXSM•Pipeline and launch updates
AUVELITY launched for Alzheimer’s agitation in June.
The FDA accepted the AXS-12 NDA for narcolepsy cataplexy with a May 1, 2027 PDUFA date.
Quarterly revenue and loss widen
Axsome posted 2Q 2026 net product revenue of $218.4 million, up 46% year over year.
Net loss widened to $51.3 million, or $(0.99) per share.
Product sales growth led by AUVELITY and SUNOSI
AUVELITY net product sales rose 51% to $180.3 million.
SUNOSI net product revenue increased 20% to $35.8 million.
Expenses rise with commercialization and launch costs
SG&A expenses climbed to $208.1 million from $130.3 million, driven by AUVELITY commercialization and the Alzheimer’s agitation launch.
